Theoretical concepts and the emerging role of taxanes in adjuvant therapy

Oncologist

Volumn 6, Issue SUPPL. 3, 2001, Pages 30-35

  Norton, Larry ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant; Breast cancer; Docetaxel; Gompertzian; Herceptin; Log kill; Paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL KILLING; CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; HUMAN; PRIORITY JOURNAL;

EID: 0035033569     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_3-30     Document Type: Conference Paper

References (30)

1. Malignant tumors of the breast
2. Systemic treatment of early breast cancer by hormonal, systemic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
3. Kinetics of mammary tumor cell growth and implications for therapy
4. Analysis of multiarmed trials in which animals bearing different burdens of L1210 leukemia cells were treated with two, three, and four drug combinations delivered in different ways with varying dose intensities of each drug and varying average dose intensities
5. Adjuvant breast cancer therapy: Current status and future strategies - Growth kinetics and the improved drug therapy of breast cancer
6. Kinetic concepts in the systemic drug therapy of breast cancer
7. Kinetics of breast neoplasms
8. Decelerating growth and human breast cancer
9. Conceptual basis for advances in the systemic drug therapy of breast cancer
10. A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate
11. Adjuvant drug therapy for operable breast cancer
12. Cytokinetics
13. A Gompertzian model of human breast cancer growth
14. Gompertzian growth as a self-similar and allometric process
15. Principles of cancer management: Chemotherapy
16. Evolving concepts in the systemic drug therapy of breast cancer
17. An intensive sequenced adjuvant chemotherapy regimen for breast cancer
18. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes
19. Sequential adjuvant therapy: The Memorial Sloan-Kettering Cancer Center experience
20. Improved disease free survival (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T), but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
21. Polychemotherapy for early breast cancer: An overview of the randomized trials
22. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
23. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
24. Concepts in Ras-directed therapy
25. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
26. Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibody
27. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for the treatment of human breast cancer
28. 2+/MBC) markedly increases activity: A randomised, multinational controlled phase III trial
29. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer